Author:
Cwajna Mark,Hamouda Abdelrahman M.,Kendall Nicholas,Ghozy Sherief,Elder Benjamin D.,Kallmes David F.
Publisher
Springer Science and Business Media LLC
Reference7 articles.
1. Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? BMJ (Clinical research ed). 2007;334(7585):120–3. https://doi.org/10.1136/bmj.39024.487720.68.
2. Gresham G, Meinert JL, Gresham AG, Piantadosi S, Meinert CL. Update on the clinical trial landscape: analysis of ClinicalTrials.gov registration data, 2000-2020. Trials, (2022) 23(1), 858. https://doi.org/10.1186/s13063-022-06569-2.
3. Hyman P, McNamara PC. Food and Drug Administration Amendments Act of 2007 Summary and Analysis. Published October 17, 2007. https://hpm.com/wp-content/uploads/2007/10/HPM-FDAAA-Summary-and-Analysis.pdf. Accessed 25 Mar 2024
4. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. The New England journal of medicine, (2015) 372(11), 1031–1039. https://doi.org/10.1056/NEJMsa1409364.
5. U.S. Food and Drug Administration (no date) FDA. Available at: https://www.fda.gov/media/148036/ (Accessed: 26 March 2024).